Clinical trial
Phase I FOLFOX Combination
NCT00499850 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00499850 |
|---|---|
| Title | Phase I FOLFOX Combination |
| Official title | A Phase I,Open Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as First and Second Line Therapy in Patients With Advanced Colorectal Adenocarcinoma. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Colorectal Carcinoma |
| Intervention type | Drug |
| Interventions | ZD6474 (vandetanib), 5-Fluorouracil, Leucovorin, Oxaliplatin |
| Enrollment | 18 |
| Start date | Aug 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Apr 1, 2008 |
| First posted | Jul 12, 2007 |
| Last update posted | Aug 25, 2016 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: